Are you on the hunt for some big returns to take your portfolio to the next level? If you are, then read on!
That's because the ASX 200 shares listed below have been named as buys and tipped to rise strongly from where they currently trade.
Here's what brokers are saying about them:
Image source: Getty Images
Clarity Pharmaceuticals Ltd (ASX: CU6)
The team at Bell Potter thinks that Clarity Pharmaceuticals could be an ASX 200 share to buy for big returns.
It is a pharmaceuticals company focused on the development of targeted copper theranostics (TCT) for the imaging and treatment of select cancers.
Bell Potter was pleased with the company's recent capital raising and believes it is now fully funded for its full clinical program. As a result, the broker put a speculative buy rating and $5.70 price target on the ASX 200 share. This suggests that upside of 55% is possible between now and this time next year (with potentially even more). It explains:
CU6 is now funded to complete the full clinical program in prostate cancer including both imaging trials and a future approval study for its therapeutic ( 67Cu SAR bis PSMA). The certainty of the funding decreases the overall risk profile of the group in addition to providing a stronger position from which to negotiate future terms of a distribution deal in the US. Valuation raised to $5.70. On an un-risked basis (reducing clinical trial risk to nil for mCRPC only), the valuation increases to ~$13 representing a market cap of A$4.8bn (US$3.1bn) which is not unreasonable compared to prior transactions in the sector.
Treasury Wine Estates Ltd (ASX: TWE)
The team at Morgans thinks that this wine giant's shares are being seriously undervalued by the market.
In response to its full year results release last week, the broker retained its buy rating with a $10.10 price target. This implies potential upside of approximately 30% for investors over the next 12 months. It said:
TWE's FY25 result was in line with guidance, reporting a credible 17% growth in EBITS during a period of macro-economic and category headwinds. TWE is targeting further EBITS growth in FY26, led by Penfolds. We have made modest changes to our forecasts reflecting the disruption associated with a change of distributor in California. While lacking near term share price catalysts given industry and macro headwinds and a CEO transition, trading on an FY26F PE of only 12.7x, we maintain a BUY rating. A$200m share buyback should provide some degree of share price support.
